Stock Research for ALPMF

ALPMF

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

ALPMF Stock Chart & Research Data

The ALPMF chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ALPMF chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


ALPMF Due diligence Resources & Stock Charts

The ALPMF stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View ALPMF Detailed Price Forecast - CNN Money CNN View ALPMF Detailed Summary - Google Finance
Yahoo View ALPMF Detailed Summary - Yahoo! Finance Zacks View ALPMF Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View ALPMF Trends & Analysis - Trade-Ideas Barrons View ALPMF Major Holders - Barrons
NASDAQ View ALPMF Call Transcripts - NASDAQ Seeking View ALPMF Breaking News & Analysis - Seeking Alpha
Spotlight View ALPMF Annual Report - CompanySpotlight.com OTC Report View ALPMF OTC Short Report - OTCShortReport.com
TradeKing View ALPMF Fundamentals - TradeKing Charts View ALPMF SEC Filings - Bar Chart
WSJ View Historical Prices for ALPMF - The WSJ Morningstar View Performance/Total Return for ALPMF - Morningstar
MarketWatch View the Analyst Estimates for ALPMF - MarketWatch CNBC View the Earnings History for ALPMF - CNBC
StockMarketWatch View the ALPMF Earnings - StockMarketWatch MacroAxis View ALPMF Buy or Sell Recommendations - MacroAxis
Bullish View the ALPMF Bullish Patterns - American Bulls Short Pains View ALPMF Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View ALPMF Stock Mentions - StockTwits PennyStocks View ALPMF Stock Mentions - PennyStockTweets
Twitter View ALPMF Stock Mentions - Twitter Invest Hub View ALPMF Investment Forum News - Investor Hub
Yahoo View ALPMF Stock Mentions - Yahoo! Message Board Seeking Alpha View ALPMF Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for ALPMF - SECform4.com Insider Cow View Insider Transactions for ALPMF - Insider Cow
CNBC View ALPMF Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for ALPMF - OTC Markets
Yahoo View Insider Transactions for ALPMF - Yahoo! Finance NASDAQ View Institutional Holdings for ALPMF - NASDAQ


Stock Charts

FinViz View ALPMF Stock Insight & Charts - FinViz.com StockCharts View ALPMF Investment Charts - StockCharts.com
BarChart View ALPMF Stock Overview & Charts - BarChart Trading View View ALPMF User Generated Charts - Trading View




Latest Financial News for ALPMF


Astellas Pharma gets U.S. nod for blood cancer treatment
Posted on Wednesday November 28, 2018

The U.S. Food and Drug Administration on Wednesday approved a blood cancer treatment from Japan's Astellas Pharma Inc, making it the first targeted therapy to treat patients with a certain mutation. The treatment, Xospata, was approved for patients with acute myeloid leukemia (AML) with a FLT3 mutation, whose cancer has relapsed or proved treatment-resistant. The drug, taken once a day in tablet form, will have a wholesale acquisition cost of $22,500 for a month's supply, Astellas said.


Pfizer, Astellas revise two cancer drug trial protocols to speed up results
Posted on Wednesday August 22, 2018

The companies now expect the ARCHES trial to end late this year, ahead of the previously anticipated completion date of April 2020, and the EMBARK trial to complete by mid-2020, earlier than the prior goal of March 2021. Both trials are testing Xtandi in men with hormone-sensitive prostate cancer. Xtandi is already approved in the United States to treat castration-resistant prostate cancer and brought Pfizer revenue of $171 million in the latest reported quarter.


Astellas Is Considering Selling Europe Assets to Raise Cash
Posted on Wednesday July 18, 2018

Astellas Pharma Inc. is considering a sale of some central and eastern European assets as the Japanese drugmaker seeks to trim its portfolio and raise cash, according to people familiar with the matter. Astellas is working with Jefferies Financial Group Inc. on the potential disposal, which includes Russian assets and has drawn interest from private equity firms and other pharmaceutical companies, the people said, asking not to be identified because the deliberations are private. The portfolio under review includes drugs to prevent infections and pain treatments, the people said.


Pfizer's Xtandi Gets FDA Nod for Expanded Patient Population
Posted on Monday July 16, 2018

FDA approves Pfizer's (PFE) sNDA to expand the label of Xtandi to include the non-metastatic prostate cancer patient population.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.